Bio-Rad Laboratories, Inc. Class A Common Stock vs Quantum Computing Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Quantum Computing Inc trades at $8.89 (market cap $2.03B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.6× Quantum Computing Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| BIO | QUBT | |
|---|---|---|
Market Cap | $9.43B | $2.03B |
Sector | Health | Technology |
52-Week High | $356.25 | $24.62 |
52-Week Low | $241.71 | $6.31 |
Enterprise Value | $9.18B | $1.09B |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
Quantum Computing Inc. (QUBT) trades at $8.92, down slightly by 0.11% on the day, with a bearish technical signal. The company is in a high-growth but pre-profit phase, reporting Q2 2026 revenue of $5.6 million (MarketBeat, 2026-08-10), a significant increase, but with persistent net losses. Analyst sentiment is positive with a 75% buy rating and a consensus price target of $18.50, indicating substantial upside potential from current levels.
The outlook for QUBT is speculative, offering high growth potential in quantum computing and photonics, supported by strong institutional interest and revenue expansion. Key risks include steep valuation (P/S of 189.05), ongoing losses, high cash burn, and competitive pressures in the emerging quantum sector, requiring careful risk assessment by investors.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →